Noelle Callizot, PharmD, PhD, HDR

Co-founder & Chief scientific officer (CSO). Biotech CRO (in vitro and in vivo activities) specialized in neurodegenerative diseases. Drug development services : advice in therapeutic strategy and indication (from screening to candidate molecule stage). Regulatory advices and drafting (IB, IMPD, IND etc…) * Member of scientific advisory boards of various biotechs and start-ups : INFLECTIS Biosciences SAS, AXOLTIS Pharma, NEURALIA (co-founder), NEURON REHAB (co-founder), NEURADOM (co-founder), ... * AFM-TELETHON : Permanent member of the Scientific Council (French association for the fight against myopathies). Co-President of the Pharmacology Commission AFM. President of Strategic and Therapeutic Orientation Committees (COSET)

* ALZPROTECT SAS (Loos, France): Director of Pharmaceutical Development and Chief Scientific Officer (CSO). Implementation of preclinical Pharmacological, ADME and Toxicological studies. Setting up of "early stage" clinical trials, proof of concept clinical study, Phase 1, 2a-b. in PSP indication (progressive supranuclear paralysis). Development strategy for molecules from the new entity stage to Candidate stages in "neuro" indication. Drafting of regulatory documents: IB, IMPD, CTX, IND, ODD...

Neuron Experts (CRO). Head of Research and development, cell models development of AD, PD, ALS, HD..., development of new protocols of primary cell cultures. Writing of neurological research projects and protocols for biotechs and big pharmas. CTX / IND, regulatory requirements and submission knowledge., Writing of patents, abstracts, publications and communications, posters, external presentations. Business Development director

Consultancy for big pharma, biotech and academia -Expertise in the pharmaceutical development (preclinical and clinical) for neuroprotective and neurotrophic drugs of neurodegenerative diseases (ALS, PD, AD, neuropathies…). -Key opinion leader network in neurology areas. -Expertise in pre-clinical models of neurodegenerative diseases: -Animal facilities expertise (rodents and transgenic animals) -Writing of neurological research projects and protocols for biotechs and big pharmas. CTX / IND, regulatory requirements and submission knowledge., Writing of patents, abstracts, publications and communications, posters, external presentations. -Business development advices (for “out and in licensing” strategies)

Head of NeuroPharmacology, New opportunity manager -Responsibility of staff people (2 PhD, 1 research assistant). -In charge of pre-clinical vitro and vivo pharmacology programs for 2 compounds under development for Alzheimer (Ph IIa) and ALS diseases (PhI). -Dealing with external CRO and academia. -New opportunities manager (identification, evaluation and searches of new research programs in accordance with business strategy and marketing, advice for new indications for compounds under development)

Manager of Neurofit department - Shareholder -Management of 15 staff (PhD, research assistant, animal care and administrative staff), -Budget setting up -Management of the merge between Neuro3D SA and Neurofit SA

Member of the Board (Majority shareholder) -Management of 15 staff (PhD, research assistant, animal care and administrative staff), -Budget setting up -Coordination of research and development programs and contracted projects for in vivo and in vitro departments, animal facilities supervisor.

Role of the amyloid peptide oligomer as a physiological neurotransmitter, conditions under which it may become toxic to neurons (Rôle du peptide bêta-amyloïde comme neurotransmetteur physiologique; conditions dans lesquelles ce dernier peut devenir toxique pour les neurones).

SCIENTIFIC INTERESTS AND EXPERIMENTAL TECHNIQUES Neurodegenerative diseases expertise (Induced neuropathies, ALS, MS, Alzheimer, Parkinson’s disease) -Models of induced neuropathies, ALS, motoneuron degeneration, multiple sclerosis in rats and mice -Pain model: neuropathic pain, acute and chronic pain. -Parkinson and Alzheimer models in rodents -Techniques : tests of motor coordination; tests of muscular force, thermosensitivity, memory tests… -Electromyography (EMG): M wave, CMAP, H wave, F wave, SNCV (conduction of caudal, sciatic, tibial nerves…). -Phenotyping of transgenic/KO mice expertise -In vitro models (DRG, Spinal cord motoneurons, cortical, mesencephalic neurones …) of degeneration (induced with glutamate, Mpp+, vincristine, ... ). -Neurotoxicity Morphology / histology Immunohistology , morphometric analysis nerves, DRG, spinal cord, brain...

Expertise in Pharmaceutical development